Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

K. E. Caudle, C. F. Thorn, T. E. Klein, J. J. Swen, H. L. McLeod, Robert B Diasio, M. Schwab

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)640-645
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume94
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Dihydrouracil Dehydrogenase (NADP)
Pharmacogenetics
Genotype
Guidelines
Enzymes
Genes
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. / Caudle, K. E.; Thorn, C. F.; Klein, T. E.; Swen, J. J.; McLeod, H. L.; Diasio, Robert B; Schwab, M.

In: Clinical Pharmacology and Therapeutics, Vol. 94, No. 6, 12.2013, p. 640-645.

Research output: Contribution to journalArticle

Caudle, K. E. ; Thorn, C. F. ; Klein, T. E. ; Swen, J. J. ; McLeod, H. L. ; Diasio, Robert B ; Schwab, M. / Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. In: Clinical Pharmacology and Therapeutics. 2013 ; Vol. 94, No. 6. pp. 640-645.
@article{4d52c955f737424c8b9ed975c7926395,
title = "Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing",
abstract = "The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).",
author = "Caudle, {K. E.} and Thorn, {C. F.} and Klein, {T. E.} and Swen, {J. J.} and McLeod, {H. L.} and Diasio, {Robert B} and M. Schwab",
year = "2013",
month = "12",
doi = "10.1038/clpt.2013.172",
language = "English (US)",
volume = "94",
pages = "640--645",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

AU - Caudle, K. E.

AU - Thorn, C. F.

AU - Klein, T. E.

AU - Swen, J. J.

AU - McLeod, H. L.

AU - Diasio, Robert B

AU - Schwab, M.

PY - 2013/12

Y1 - 2013/12

N2 - The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).

AB - The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).

UR - http://www.scopus.com/inward/record.url?scp=84888012165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888012165&partnerID=8YFLogxK

U2 - 10.1038/clpt.2013.172

DO - 10.1038/clpt.2013.172

M3 - Article

C2 - 23988873

AN - SCOPUS:84888012165

VL - 94

SP - 640

EP - 645

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -